Better Together: AI/ML, PBPK and QSP/QST Modeling in Drug Discovery & Development

Better Together: AI/ML, PBPK and QSP/QST Modeling in Drug Discovery & Development

Software: DILIsym®, GastroPlus®

Modeling and simulation offer useful predictions that can help guide your drug development program—but what if you could get even more out of the available technology?

Development of Successful Physiologically-Based Pharmacokinetic (PBPK) Models

Development of Successful Physiologically-Based Pharmacokinetic (PBPK) Models

Authors: Idkaidek N
Publication: Jordan Journal of Pharmaceutical Sciences
Software: GastroPlus®

Physiologically-based pharmacokinetic (PBPK) modeling is a strong mathematical tool that integrates body physiology, drug physicochemical properties...

Teaching of Drug Disposition using Physiologically Based Pharmacokinetic Modeling Software: GastroPlus as an Educational Tool

Teaching of Drug Disposition using Physiologically Based Pharmacokinetic Modeling Software: GastroPlus as an Educational Tool

Publication: Adv Physiol Educ
Software: GastroPlus®

Physiologically based pharmacokinetic (PBPK) modeling requires understanding of chemical, physiologic, and pharmacokinetic principles.

Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space

Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space

Publication: J Pharm Pharm Sci
Software: GastroPlus®

The use of physiologically based biopharmaceutics modeling (PBBM) and bioequivalence safe space is increasingly common for immediate-release drug products.

Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs

Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs

Publication: Cancer Chemother Pharmacol
Software: GastroPlus®

Physiologically based pharmacokinetics (PBPK) models are increasingly used in the drug research and development, especially in anti-cancer drugs.

Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions

Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions

Publication: Eur J Drug Metab Pharmacokinet
Division: PBPK

Index substrates and inhibitors to investigate the role of the polymorphic enzyme, cytochrome P450 (CYP) 2D6, in the metabolism of new compounds have been proposed by regulatory agencies.